Second Generation Proteasome Inhibitors in Multiple Myeloma

Author(s): Alessandro Gozzetti*, Giulia Papini, Veronica Candi, Corrado Zuanelli Brambilla, Santina Sirianni, Monica Bocchia

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 7 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies. Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming soon.

Keywords: Myeloma, bortezomib, new proteasome inhibitors, carfilzomib, oprozomib.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [920 - 926]
Pages: 7
DOI: 10.2174/1871520616666160902101622
Price: $65

Article Metrics

PDF: 79
HTML: 19